Wednesday, April 24, 2024 11:48:06 AM
+------------------------++------------------------++-----------------------+
¦ Num Analysts: ¦ 5 ¦¦ Quick Ratio: ¦ 13.12 ¦¦ TrailingEps: ¦ -1.64 ¦
¦ Recommendation: ¦ BUY ¦¦ Current Ratio: ¦ 14.41 ¦¦ ForwardEps: ¦ -0.78 ¦
¦ TargetLow: ¦ 7.0 ¦¦ PEG Ratio: ¦ 0.02 ¦¦ DebtEqRatio: ¦ 0.46 ¦
¦ TargetHigh: ¦ 39.0 ¦¦ Short Ratio: ¦ 0.99 ¦¦ Cash: $ ¦ 51.1M ¦
¦ TargetMean: ¦ 15.6 ¦¦ Price/Book: ¦ 0.61 ¦¦ Debt: $ ¦ 383.0K ¦
¦ TargetMedian: ¦ 10.0 ¦+------------------------++-----------------------+
+------------------------+
Nothing that I say or post is financial advice. Buy and sell at your own risk.
If you need financial advice, consult a psychic.
-Ralfito
Recent ELDN News
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:15:13 AM
- Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection • GlobeNewswire Inc. • 05/07/2024 11:05:00 AM
- Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/28/2024 08:01:00 PM
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection • GlobeNewswire Inc. • 03/25/2024 08:56:42 PM
- Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human • GlobeNewswire Inc. • 03/21/2024 02:31:12 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:35:28 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:01:53 PM
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/14/2024 12:01:00 AM
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook • GlobeNewswire Inc. • 01/04/2024 09:40:44 PM
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/04/2023 11:00:00 PM
- Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference • GlobeNewswire Inc. • 11/29/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:00:32 PM
- Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 11/09/2023 09:01:00 PM
- Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:30:17 PM
- Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation • GlobeNewswire Inc. • 11/02/2023 01:05:00 PM
- Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer • GlobeNewswire Inc. • 10/23/2023 11:00:00 AM
- Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting • GlobeNewswire Inc. • 10/13/2023 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:19:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:17:59 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 09:51:47 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2023 09:08:23 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM